MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Myriad Genetics Company Profile (NASDAQ:MYGN)

Consensus Ratings for Myriad Genetics (NASDAQ:MYGN) (?)
Ratings Breakdown: 6 Hold Rating(s), 9 Buy Rating(s)
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $42.92 (43.08% upside)

Analysts' Ratings History for Myriad Genetics (NASDAQ:MYGN)
Show:
DateFirmActionRatingPrice TargetActions
5/4/2016Bank of AmericaReiterated RatingHold$39.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/4/2016Leerink SwannReiterated RatingMarket Perform$44.00 -> $41.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/4/2016Avondale PartnersLower Price TargetMarket Outperform$50.00 -> $47.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/4/2016MizuhoReiterated RatingNeutral$42.00 -> $34.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/23/2016Goldman SachsBoost Price Target$40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/3/2016Deutsche BankReiterated RatingBuy$52.00 -> $51.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/7/2016Cowen and CompanyBoost Price Target$40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/7/2016BarclaysBoost Price TargetOverweight$50.00 -> $52.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/27/2015Piper JaffrayReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/20/2015William BlairReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/16/2015StephensBoost Price TargetOverweight$42.00 -> $47.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/15/2015Jefferies GroupBoost Price TargetHold$32.00 -> $38.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/25/2015Wells FargoUpgradeMarket Perform -> OutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/12/2015JMP SecuritiesLower Price TargetMarket Outperform$46.00 -> $40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/21/2015GabelliInitiated CoverageBuy$42.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/28/2015Credit SuisseReiterated RatingUnderperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/7/2015Cantor FitzgeraldReiterated RatingBuy$43.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/4/2015OppenheimerReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/10/2014Morgan StanleyInitiated CoverageUnderperform -> Underperform$25.00 -> $34.89View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/14/2014SunTrustBoost Price Target$22.00 -> $26.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/30/2014RBC CapitalBoost Price TargetSector Perform$31.00 -> $40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/25/2014 forward)
Earnings History for Myriad Genetics (NASDAQ:MYGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/9/2016        
5/3/2016Q316$0.38$0.41$185.08 million$190.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/2/2016Q216$0.41$0.45$189.99 million$193.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2015Q116$0.35$0.41$177.89 million$183.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2015Q415$0.42$0.41$187.81 million$189.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2015Q315$0.39$0.40$183.30 million$180.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/3/2015Q215$0.35$0.40$183.41 million$184.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2014Q115$0.32$0.25$175.00 million$168.84 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2014Q414$0.46$0.48$187.68 million$188.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2014Q314$0.45$0.48$175.23 million$182.92 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/4/2014Q214$0.46$0.66$176.02 million$204.06 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2013Q114$0.46$0.68$167.64 million$202.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2013Q4 2013$0.44$0.53$159.87 million$174.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2013Q3 2013$0.39$0.46$148.25 million$156.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/5/2013Q2 2013$0.38$0.42$143.71 million$140.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2012Q113$0.32$0.36$129.84 million$133.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/14/2012$0.34$0.34ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/1/2012$0.32$0.34ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/31/2012$0.31$0.33ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/1/2011$0.27$0.29ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/9/2011$0.29$0.30ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/3/2011$0.25$0.31ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/27/2011$0.26$0.26ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Myriad Genetics (NASDAQ:MYGN)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163$0.37$0.38$0.38
Q2 20164$0.41$0.43$0.42
Q3 20161$0.42$0.42$0.42
Q4 20162$0.36$0.45$0.41
Q1 20172$0.42$0.45$0.44
Q2 20171$0.46$0.46$0.46
Q3 20171$0.43$0.43$0.43
Q4 20171$0.38$0.38$0.38
(Data provided by Zacks Investment Research)
Dividend History for Myriad Genetics (NASDAQ:MYGN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Myriad Genetics (NASDAQ:MYGN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/21/2016Alexander FordInsiderSell18,637$30.87$575,324.19View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/6/2016Gary A KingVPSell15,000$39.03$585,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2016Gary A KingVPSell15,000$38.12$571,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/11/2015Walter Phd GilbertDirectorSell5,000$42.23$211,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/8/2015S. Louise PhanstielDirectorSell5,000$44.00$220,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/5/2015Heinrich DreismannDirectorSell60,000$44.44$2,666,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/4/2015Richard M. MarshVPSell35,000$44.50$1,557,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/28/2015Gary A. KingVPSell10,000$42.82$428,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/28/2015Jerry S. LanchburyinsiderSell50,962$41.86$2,133,269.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/27/2015Jerry S. LanchburyinsiderSell24,767$41.80$1,035,260.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/17/2015Jerry S. LanchburyinsiderSell60,270$39.89$2,404,170.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2015Richard M. MarshVPSell35,000$41.25$1,443,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/14/2015Gary A. KingVPSell14,562$39.41$573,888.42View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2015Gary A. KingVPSell25,438$39.41$1,002,511.58View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/2/2015Gary A. KingVPSell15,000$38.23$573,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/28/2015Gary A. KingVPSell30,000$35.73$1,071,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2014Gary A KingVPSell6,568$39.95$262,391.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/30/2014James S EvansCFOSell21,850$38.99$851,931.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/24/2014James S EvansCFOSell8,790$37.98$333,844.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/23/2014James S EvansCFOSell110,463$37.89$4,185,443.07View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/14/2014Peter D MeldrumInsiderSell24,000$39.50$948,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/5/2014John T HendersonDirectorSell5,000$35.70$178,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/9/2014Ronald RogersVPSell12,500$36.01$450,125.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/30/2014Richard MarshVPSell30,000$41.80$1,254,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/23/2014Richard MarshVPSell31,516$39.80$1,254,336.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/16/2014Richard MarshVPSell28,484$39.80$1,133,663.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/7/2014Jayne HartVPSell79,000$40.90$3,231,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/2/2014James EvansCFOSell80,000$40.00$3,200,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/2/2014Peter MeldrumInsiderSell55,000$39.57$2,176,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/19/2014Peter MeldrumInsiderSell55,000$37.00$2,035,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2014Peter MeldrumInsiderSell55,000$35.15$1,933,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/12/2014Richard MarshVPSell50,000$34.37$1,718,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/26/2014Walter Phd GilbertDirectorSell30,000$37.58$1,127,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/25/2014Mark Christopher CaponeInsiderSell95,250$37.83$3,603,307.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/24/2014Gary KingVPSell20,000$38.00$760,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/20/2014James EvansCFOSell30,000$36.01$1,080,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/20/2014Robert Gardner HarrisonInsiderSell17,554$36.22$635,805.88View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/19/2014Richard MarshVPSell34,676$34.71$1,203,603.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/19/2014Walter Phd GilbertDirectorSell60,000$34.48$2,068,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/18/2014Gary KingVPSell25,000$34.74$868,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/18/2014Heinrich DreismannDirectorSell30,000$35.00$1,050,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/14/2014Richard MarshVPSell20,960$31.50$660,240.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/12/2014Robert Gardner HarrisonInsiderSell13,707$30.74$421,353.18View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/10/2014Mark Christopher CaponeInsiderSell87,500$32.07$2,806,125.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/7/2014James EvansCFOSell35,000$33.04$1,156,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/5/2014Peter MeldrumInsiderSell123,940$31.10$3,854,534.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/8/2013James EvansCFOSell8,072$26.50$213,908.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/8/2013Peter MeldrumInsiderSell31,784$26.50$842,276.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/13/2013Robert Gardner HarrisonInsiderSell31,498$36.17$1,139,282.66View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2013Mark Christopher CaponeInsiderSell79,999$33.23$2,658,366.77View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/14/2013Peter D MeldrumInsiderSell15,000$34.00$510,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/10/2013Heinrich DreismannDirectorSell30,000$31.16$934,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/10/2013Peter D MeldrumInsiderSell75,960$31.99$2,429,960.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/10/2013Richard M MarshVPSell48,192$33.00$1,590,336.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/4/2012Jerry S LanchburyInsiderSell3,900$28.50$111,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/3/2012Jerry S LanchburyInsiderSell3,000$28.50$85,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/14/2012Peter D MeldrumInsiderSell20,000$27.60$552,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/13/2012James S EvansCFOSell5,494$27.10$148,887.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Myriad Genetics (NASDAQ:MYGN)
DateHeadline
06/24/16 07:57 AMPrice Target Update on Myriad Genetics (NASDAQ:MYGN) - Trade Calls
06/16/16 05:30 PMMyriad Genetics, Inc. (NASDAQ:MYGN) Yearly Sales Estimate At $1216 - Investor Newswire
06/13/16 04:56 PMMyriad Genetics Inc. (MYGN) Dropped To A 9-Month Low
06/13/16 08:17 AMTwo Stocks within Traders Observation: Myriad Genetics, Inc. (NASDAQ:MYGN) , SeaWorld Entertainment, Inc. (NYSE ... - Street Updates
06/13/16 08:17 AMStocks in Analyst's Eyes: Myriad Genetics, Inc. (NASDAQ:MYGN), DHT Holdings, Inc. (NYSE:DHT) - Beacon Chronicle
06/11/16 05:31 PMWill Myriad Genetics, Inc. (NASDAQ:MYGN) Surprise Analysts? - Investor Newswire
06/11/16 05:31 PMTrending Stock Analysis: Myriad Genetics, Inc. (NASDAQ:MYGN) - News Oracle
06/11/16 08:12 AMMyriad Genetics, Inc. Stock Momentum Hits Extreme Weakness - CML News
06/11/16 08:12 AMAnalysts Rating updates about two Stocks: Myriad Genetics, Inc. (NASDAQ:MYGN) , Golar LNG Limited (NASDAQ:GLNG) - Street Updates
06/10/16 05:38 PMOversold Conditions For Myriad Genetics (MYGN) - Nasdaq
06/09/16 05:41 PMMyriad Genetics, Inc. (NASDAQ:MYGN) Fundamental Star Rating Report - CML News
06/09/16 08:17 AMMyriad Genetics To Participate In Goldman Sachs Healthcare Conference At 1:00 PM
06/07/16 08:53 AMMyriad Gets $200 Million More For Share Repurchase Program - Myriad Genetics, Inc. (Nasdaq: MYGN) revealed that its board has approved an additional $200 million authorization for its share buyback program. According to the company, as of the end of the third quarter of fiscal year 2016, it bought back higher than $1.1 billion of stock since the inception of the program ...Full story available on Benzinga.com
06/07/16 08:26 AMMYRIAD GENETICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
06/07/16 07:59 AMMyriad Genetics (MYGN) Adds $200M to Buyback Plan - StreetInsider.com
06/07/16 07:59 AMMYRIAD GENETICS INC. (NASDAQ:MYGN) Financial Condition Compared to S&P 500 - CML News
06/07/16 06:20 AMMyraid Genetics increases share buyback program by $200 million -
06/07/16 06:18 AMMyriad Board Approves $200 Million Increase in Share Repurchase Program - [at noodls] - SALT LAKE CITY, June 07, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that its board of directors has approved an additional $200 million authorization for its share repurchase ...
06/06/16 05:15 PMMyriad Genetics : myRisk® Hereditary Cancer Test Demonstrates the Magnitude of Breast and Ovarian Cancer Risk in Nearly 100,000 Patients
06/06/16 05:15 PMMyriad Genetics to Present at the 2016 Goldman Sachs Healthcare Conference
06/05/16 05:20 PMMyriad Genetics Inc.: Myriad Will Present Three New Hereditary Cancer Studies at the ASCO Annual Meeting - The Wall Street Transcript
06/05/16 05:20 PMMyriad Genetics, Inc. (MYGN) Receives “Neutral” Rating from Mizuho - Let Me Know About This
06/05/16 07:59 AMPerformance Review for Myriad Genetics, Inc. (NASDAQ:MYGN) - HNN
06/05/16 07:59 AMMyriad Genetics, Inc. (MYGN) Rating Reiterated by Bank of America - Let Me Know About This
06/05/16 07:59 AMMyriad Genetics, Inc. (MYGN) Price Target Cut to $47.00 by Analysts at Avondale Partners - Let Me Know About This
06/05/16 06:18 AMMyriad Will Present Three New Hereditary Cancer Studies at the ASCO Annual Meeting - [at noodls] - SALT LAKE CITY, June 05, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that results from three studies with ...
06/03/16 05:48 PMAnalyst Overview on These Stocks: Navistar International Corporation (NYSE:NAV), Myriad Genetics, Inc. (NASDAQ ... - Beacon Chronicle
06/03/16 05:48 PMTarget Price Watch for Myriad Genetics, Inc. (NASDAQ:MYGN) - HNN
06/02/16 05:43 PMEarnings Expectations Overview: Snyder's-Lance, Inc. (NASDAQ:LNCE), Myriad Genetics, Inc. (NASDAQ:MYGN) - Beacon Chronicle - Beacon ChronicleEarnings Expectations Overview: Snyder's-Lance, Inc. (NASDAQ:LNCE), Myriad Genetics, Inc. (NASDAQ:MYGN)Beacon ChronicleLast Trade: The Company closed its last session at $31.09 with the gain of 0.58%. The market capitalization of the company is $2.92 Billion, with the average Volume of 642.21K. The stock currently has its 52-Week High range of $39.1 and 52-week low ...and more »
06/02/16 08:17 AMMyriad Genetics Inc (NASDAQ:MYGN) in Good Position - Street Report - Schaeffers Research (blog)Myriad Genetics Inc (NASDAQ:MYGN) in Good PositionStreet Report[EDGAR] Myriad Genetics Inc (NASDAQ:MYGN)(TREND ANALYSIS) issued a press release relating to the Company's acquisition of Sividon Diagnostics GmbH. On its conference call announcing the acquisition Myriad also delivered a slide presentation.Analyst Update: Intercept Pharmaceuticals Inc, Relypsa Inc, and Myriad Genetics, Inc.Schaeffers Research (blog)Short Data Review: Myriad Genetics, Inc. (NASDAQ:MYGN)Franklin IndependentMyriad Genetics (MYGN) Acquries Sividon Diagnostics for Up to EUR50MStreetInsider.comVanguard Tribune -RealistInvestor.com -Risers & Fallersall 19 news articles »
06/01/16 12:24 PMMyriad Genetics buys breast cancer prognostic firm for up to €50M -
06/01/16 10:07 AMWhat Are IBB’s Holdings’ Moving Averages? -
06/01/16 08:15 AMMyriad Genetics, Inc. (NASDAQ:MYGN) Analyst Perspective on the Stock - Stock Tick Tock - Myriad Genetics, Inc. (NASDAQ:MYGN) Analyst Perspective on the StockStock Tick TockAnalysts on Wall Street have a future 12 month target price of $39.666 on Myriad Genetics, Inc. (NASDAQ:MYGN) shares. Analysts study the companies they cover in order to present the sell-side institutions with the information neeeded to make investment ...and more »
05/31/16 05:36 PMMyriad Genetics, Inc. (NASDAQ:MYGN) Quarterly EPS Estimate At $0.42 - Investor Newswire - Myriad Genetics, Inc. (NASDAQ:MYGN) Quarterly EPS Estimate At $0.42Investor NewswireFirst Call stated that Myriad Genetics, Inc. (NASDAQ:MYGN) can touch $39.08 in coming one year. For the next quarter, the per-share earnings target is $0.42 and for ongoing fiscal at $1.65. EPS target for next year is $1.81 versus the mean EPS of $1.48 ...and more »
05/31/16 05:36 PMMyriad Genetics (MYGN) Acquries Sividon Diagnostics for Up to EUR50M - StreetInsider.com - Myriad Genetics (MYGN) Acquries Sividon Diagnostics for Up to EUR50MStreetInsider.comMyriad Genetics, Inc. (NASDAQ: MYGN) announced that it has acquired Sividon Diagnostics, a leading breast cancer prognostic company, for €35 million upfront with the potential for €15 million in additional performance-based milestones. The transaction ...and more »
05/31/16 03:23 PMMyriad Acquires Sividon Diagnostics - [at noodls] - SALT LAKE CITY, May 31, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it has acquired Sividon Diagnostics, ...
05/31/16 03:18 PMMYRIAD GENETICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
05/31/16 03:06 PM4:06 pm Myriad Genetics acquires Sividon Diagnostics for EUR 35 mln upfront w/ potential for EUR 15 mln in potential performance-based future milestones -
05/31/16 04:51 AMStock Review and Earnings Check on Myriad Genetics, Inc. (NASDAQ:MYGN) - HNN - Stock Review and Earnings Check on Myriad Genetics, Inc. (NASDAQ:MYGN)HNNCompany earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Myriad Genetics, Inc. (NASDAQ:MYGN) to report quarterly EPS of $0.38. The company's next earnings report is expected to be published on ...and more »
05/31/16 04:51 AMStock Paining Investors: Myriad Genetics, Inc. (NASDAQ:MYGN) - HNN - Stock Paining Investors: Myriad Genetics, Inc. (NASDAQ:MYGN)HNNWhen a company shows a steady upwards earnings trend, it is a good indicator that the company will dominate companies with a more volatile earnings trend. Myriad Genetics, Inc. (NASDAQ:MYGN)'s trailing 12 months EPS is 1.48. Last year, their EPS ...and more »
05/30/16 04:08 PMTarget Check and Stock Performance Recap Myriad Genetics, Inc. (NASDAQ:MYGN) - HNN - Target Check and Stock Performance Recap Myriad Genetics, Inc. (NASDAQ:MYGN)HNNIn recent session activity, Myriad Genetics, Inc. (NASDAQ:MYGN) shares have traded +1.97%. Monitoring the stock price relative to moving averages may provide enhanced perspective on share performance. After a recent check, the stock has been recorded ...and more »
05/30/16 04:08 PMNext Weeks Broker Price Targets For Myriad Genetics, Inc. (NASDAQ:MYGN) - Share Trading News - Next Weeks Broker Price Targets For Myriad Genetics, Inc. (NASDAQ:MYGN)Share Trading News05/04/2016 – Myriad Genetics, Inc. had its “market outperform” rating reiterated by analysts at Avondale Partners. They now have a USD 47 price target on the stock. 05/04/2016 – Myriad Genetics, Inc. had its “neutral” rating reiterated by analysts at ...and more »
05/29/16 07:00 AMPerformance at a Glance on Myriad Genetics, Inc. (NASDAQ:MYGN) - HNN - Performance at a Glance on Myriad Genetics, Inc. (NASDAQ:MYGN)HNNWhen speculating how a given stock will perform in the future, it is important to look at how it has performed in the past. Today we will examine how Myriad Genetics, Inc. (NASDAQ:MYGN)'s stock has performed at various points in its past. Currently ...and more »
05/27/16 09:29 PMMyriad Genetics, Inc. (NASDAQ:MYGN) Sell-Side Outlook on the Shares - Stock Tick Tock - Myriad Genetics, Inc. (NASDAQ:MYGN) Sell-Side Outlook on the SharesStock Tick TockThe Wall Street sell-side, who serve as intermediaries between stock issuers and investors, have a consensus target price of $39.666 on Myriad Genetics, Inc. (NASDAQ:MYGN) shares. The most aggressive analyst target sees the stock reaching $50 within ...and more »
05/27/16 04:22 PMBull Vs. Bear: Myriad Genetics, Inc. - Motley Fool - Motley FoolBull Vs. Bear: Myriad Genetics, Inc.Motley FoolTo help answer that question, we asked two of our Motley Fool contributors to put their best case for and against investing in Myriad Genetics' stock right now. Have a look at what they say before making your own decision about the molecular ...
05/26/16 04:11 PMScopia Capital Management LP Decreased Stake in Myriad Genetics INC (NASDAQ:MYGN) by $39.05 Million as ... - CCH Daily News - Scopia Capital Management LP Decreased Stake in Myriad Genetics INC (NASDAQ:MYGN) by $39.05 Million as ...CCH Daily NewsMatt Sirovich decreased its stake in Myriad Genetics Inc (NASDAQ:MYGN) by 16.34% based on its latest 2016Q1 regulatory filing with the SEC. Scopia Capital Management Lp sold 1.06 million shares as the company's stock declined 12.61% while stock ...and more »
05/25/16 03:57 PMMyriad Genetics, Inc. (NASDAQ:MYGN) Stock Update & Estimates - Stock Tick Tock - Myriad Genetics, Inc. (NASDAQ:MYGN) Stock Update & EstimatesStock Tick TockThe consensus on Wall Street is expecting Myriad Genetics, Inc. (NASDAQ:MYGN) to post earnings of $0.38 per share when the firm next reports it's fiscal quarterly results. According to the latest information available the report will likely be issued ...and more »
05/25/16 10:14 AMBull Vs. Bear: Myriad Genetics, Inc. - Here's the case for, and against, buying Myriad Genetics stock.
05/25/16 07:07 AMMyriad Genetics, Inc. (NASDAQ:MYGN) Closes At $34.33 - Stocks Daily - Myriad Genetics, Inc. (NASDAQ:MYGN) Closes At $34.33Stocks DailyThe technical analysis of Myriad Genetics, Inc. (NASDAQ:MYGN) stock highlights the stock is $-1.86 points away -5.10% from its 50-day MA of $36.56. It is $-4.30 or -11.03% away $39.00, the 200-day Moving Average (MA) of stock. Yesterday, the stock of ...Broker Changes For Myriad Genetics, Inc. (NASDAQ:MYGN)Risers & FallersStock to Watch: Myriad Genetics, Inc (NASDAQ:MYGN)CWRU ObserverHow Many Myriad Genetics, Inc. (NASDAQ:MYGN)'s Analysts Are Bullish?Wall Street Hints and NewsShare Trading News -Benchmark Monitorall 10 news articles »
05/24/16 07:37 AMEarnings Review and Stock Rundown for Myriad Genetics, Inc. (NASDAQ:MYGN) - Wall Street Hints and News - Earnings Review and Stock Rundown for Myriad Genetics, Inc. (NASDAQ:MYGN)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Myriad Genetics, Inc. (NASDAQ:MYGN) to ...and more »
About Myriad Genetics

Myriad Genetics logoMyriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. Myriad operates through two segments: diagnostics, which provides testing and collaborative development of testing that is designed to assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to drug therapy and guide a patient's dosing, or assess a patient's risk of disease progression and disease recurrence, and other, which provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients. It offers diagnostic tests for various diseases, such as myRisk Hereditary Cancer test for hereditary cancers; myPlan Lung Cancer test for lung cancer; myPath Melanoma test for melanoma; Prolaris test for prostate cancer, and Vectra DA for rheumatoid arthritis.

Industry, Sector and Symbol:
  • Sector: Services
  • Industry: Research Services
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: MYGN
  • CUSIP: 62855J10
Key Metrics:
  • Previous Close: $30.76
  • 50 Day Moving Average: $33.27
  • 200 Day Moving Average: $37.23
  • P/E Ratio: 20.27
  • P/E Growth: 1.25
  • Market Cap: $2.11B
  • Current Quarter EPS Consensus Estimate: $1.65 EPS
Additional Links:
Myriad Genetics (NASDAQ:MYGN) Chart for Saturday, June, 25, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha